Seeking Alpha

Theodore Cohen

View as an RSS Feed
View Theodore Cohen's Comments BY TICKER:
Latest  |  Highest rated
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    Isn't that the truth?! They really have to move out smartly on the large urology centers. On the other hand, if I were the new CEO, I'd hold my cards very close to my vest and buy myself both the time and space I need to fix the company.

    I was surprised how sanguine Johnson and Schiffman were. I think the company just might reach cash-flow breakeven this year, though it will, no doubt, be later than most expected. (I was expecting them to reach 40 million in monthly revenue by May, but it looks like that will get pushed out.)

    Ted
    Feb 27 04:41 PM | Likes Like |Link to Comment
  • 5 More Stocks That Could Collapse In 2012 [View article]
    I guess you were correct.

    Ted
    Feb 27 12:39 PM | Likes Like |Link to Comment
  • Dendreon Gains Will Be Short-Lived [View article]
    Well, one of the things (among others) that needs to be done is to raise aware in the urology community. Now, it's mostly the oncs that are prescribing Provenge (I think it's 80--20, oncs to urologists). The fact is, many men who need the drug aren't be diagnosed early enough. But yes, pumping up the immune system before it's compromised is always a good thing, regardless of the disease. And if costs can be reduced, I'm all for it!

    Ted
    Feb 27 12:21 PM | Likes Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    At this point, they need to bore in on the urology community and increase 'same store sales,' It will be 120 days before they even get questions back re their EU filing, and then, quote a while before they gain approval. The focus now should be on early detection of qualified patients in the large urology centers.

    Ted
    Feb 27 12:17 PM | Likes Like |Link to Comment
  • Dendreon Gains Will Be Short-Lived [View article]
    Johnson's been on the job one month. He needs a time to 'fix' the company. The 'Street' expected. Traders have picked up their chips and moved on to more fertile ground in this quarter.
    Feb 27 11:37 AM | Likes Like |Link to Comment
  • Dendreon Gains Will Be Short-Lived [View article]
    Obviously, traders are selling and moving on. But yes...the new president is going to dig in and make this dog hunt. I think we'll see $40M revenue in April or May, and annualized, that's cash-flow breakeven.

    Ted
    Feb 27 09:31 AM | Likes Like |Link to Comment
  • 5 More Stocks That Could Collapse In 2012 [View article]
    LOL They will hit cash-flow breakeven this year.

    Ted
    Feb 27 09:22 AM | Likes Like |Link to Comment
  • 5 More Stocks That Could Collapse In 2012 [View article]
    Dendreon Reports Fourth Quarter and 2011 Year End Financial Results
    — Conference Call to be Hosted February 27, 2012 at 9:00 a.m. ET/6:00 a.m. PT —
    SEATTLE--(BUSINESS WIRE)-- February 27, 2012--Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2011. Product revenue for the year ended December 31, 2011 was $213.5 million compared to $48 million for the year ended December 31, 2010. Product revenue for the fourth quarter of 2011 was $77 million compared to $25 million for the quarter ended December 31, 2010.

    PS

    8:41 AM Dendreon (DNDN): Q4 EPS of $0.45 beats by $0.78. Revenue of $202.1M beats by $81M. Shares +2.9% premarket.

    Have a great day. Ted (;>)
    Feb 27 09:03 AM | Likes Like |Link to Comment
  • Dendreon Gains Will Be Short-Lived [View article]
    Dendreon Reports Fourth Quarter and 2011 Year End Financial Results
    — Conference Call to be Hosted February 27, 2012 at 9:00 a.m. ET/6:00 a.m. PT —
    SEATTLE--(BUSINESS WIRE)-- February 27, 2012--Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2011. Product revenue for the year ended December 31, 2011 was $213.5 million compared to $48 million for the year ended December 31, 2010. Product revenue for the fourth quarter of 2011 was $77 million compared to $25 million for the quarter ended December 31, 2010.

    The net loss for the year ended December 31, 2011 was $337.8 million, or $2.31 per share, compared to $439.5 million, or $3.18 per share for the year ended December 31, 2010. Net income in the fourth quarter of 2011 was $38.1 million or $0.26 per share, compared to a net loss of $91.8 million, or $0.64 per share, for the same period in 2010. The fourth quarter of 2011 included a royalty payment of $125 million associated with the sale of our VICTRELIS™ (boceprevir) royalty interest. Dendreon's total operating expenses, including cost of product revenue, for the year ended December 31, 2011 were $633.3 million compared to $340.2 million in 2010.

    PS

    8:41 AM Dendreon (DNDN): Q4 EPS of $0.45 beats by $0.78. Revenue of $202.1M beats by $81M. Shares +2.9% premarket.

    Have a great day. Ted (;>)
    Feb 27 09:00 AM | Likes Like |Link to Comment
  • Vical's Herpes Vaccine Headed To The Clinic [View article]
    Anything's possible. But if the vaccine demonstrates safety and efficacy early, there always is the possibility the FDA might work with the company to move it along more quickly.

    Ted
    Feb 27 07:18 AM | Likes Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    Interesting. Can you cite sources?

    Ted
    Feb 24 08:51 AM | Likes Like |Link to Comment
  • 5 More Stocks That Could Collapse In 2012 [View article]
    Bill, Dendreon announced their 4Q2011 results and full-year results for Provenge on January 5, 2012. Here’s the summary:

    Dendreon Announces Fourth Quarter Revenues and Update on Commercialization

    — Company Reports Gross PROVENGE Revenues of Approximately $82M in Q4, Gross PROVENGE Revenues of Approximately $228M in 2011 —

    SEATTLE–(BUSINESS WIRE)– Dendreon Corporation (Nasdaq: DNDN) today announced revenue for the fourth quarter ended December 31, 2011, reporting gross product revenue of approximately $82 million. This represents approximately 25% growth over the third quarter ended September 30, 2011, and approximately 230% growth compared to the fourth quarter ended December 31, 2010. In addition, Dendreon reported full-year gross revenues from PROVENGE® (sipuleucel-T) sales of approximately $228 million.

    http://bit.ly/ABsVLt

    Regarding revenue, one source I have come to trust predicts a gross revenue of $40M for April 2012, which when annualized yields roughly $500M, the cash-flow break even point for the company.

    http://bit.ly/yt19jY

    You are correct...this stock will surprise, but at this point, being 'short' going into the April-May timeframe could be bad for your health.

    Ted
    Feb 23 11:18 AM | 6 Likes Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    New time for DNDN CC on Monday:

    SEATTLE--(BUSINESS WIRE)--

    February 22, 2012 – Dendreon Corporation (Nasdaq: DNDN - News) today announced that management will host a conference call on Monday, February 27, 2012, at 9:00 a.m. ET to review fourth quarter and year-end financial results. This conference call was previously scheduled at 4:30 p.m. ET on the same date.

    Access to the discussion may be obtained as follows:

    Time: 9:00 a.m. ET / 6:00 a.m. PT
    Date: February 27, 2012
    Dial-in: 1-877-548-9590 (domestic) or +1-720-545-0037 (international);
    conference pass code: 46511476
    Webcast: http://www.dendreon.com (homepage and investor relations section)


    A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-585-8367 or +1-404-537-3406 for international callers; the conference ID number is 46511476. The replay will be available from 12:00 p.m. ET on Monday, February 27, until 11:59 p.m. ET on Monday, March 5. In addition, the webcast will be archived for on-demand listening for 90 days at http://www.dendreon.com.

    In addition, Dendreon Corporation also announced that management will present at the following conferences:

    •RBC Capital Markets’ Healthcare Conference in New York City, on February 28, 2012, at 3:35 p.m. ET
    •Citi 2012 Global Healthcare Conference in New York City, on February 29, 2012, at 2:00 p.m. ET
    The presentations will be audio webcast live and available for replay from Dendreon’s website, http://www.dendreon.com. If you are unable to listen to the live webcasts, they will be archived on the site following the presentation. To access the replays, go to the Investor Relations section of the website.

    About Dendreon

    Dendreon Corporation is a biotechnology company whose mission is to target
    Feb 22 08:05 PM | Likes Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    The logistics involved in overseas air travel are simply too complex and time-consuming. Even the slightest weather problems turns the East Coast airspace into a disaster. Better a facility in Germany, for example, with ready access to all of Western Europe.

    They'll work it out. I'm more concerned that they recognize how complex it will be to sell into the individual countries, and move quickly to bring an EU marketing partner onboard. Approval to sell within the EU is one thing, but then, each country must be tackled individually.

    Ted
    Feb 22 05:27 PM | Likes Like |Link to Comment
  • Dendreon: Overall Survival Data For Provenge From 2012 GU Poster [View article]
    It's difficult to get a handle as to what is going on. Provider sites now number close to 1,000, if not slightly more than that, with the growth, of course, coming in the community sector. By now, those who have been through 2 or 3 reimbursement cycles should feel confortable enough to prescribe more frequently, which is the source, of course, of Schiffman's sanguine outlook for a major uptake in usage during 2Q12. I still believe we will see $40M in monthly revenue in May, 2012, at the latest, which annualized is $500M and cash-flow breakeven.

    That said, EU will be a tough nut to crack, given the poor state of the economies in the Union and the pricing pressures Provenge will face. There also are uncertainties regarding how they will produce and market in the EU. That said, I am much more optimistic now, with Johnson at the helm, that the move into Europe will be accelerated and that solutions will be found to whatever pricing issues are encountered in the various countries.
    Feb 22 03:26 PM | Likes Like |Link to Comment
COMMENTS STATS
1,894 Comments
1,409 Likes